Clinical Trials Logo

Clinical Trial Summary

MSI-H is a biomarker for solid tumors benefiting from immunotherapy. Recent clinical studies have confirmed that PD-1 inhibitors have a good effect on MSI-H advanced colorectal cancer for first- or second-line treatment. The overall effective rate is 30% to 40%. However, about 30% of patients are resistant to PD-1 inhibitors. Whether PD-1 inhibitors and existing chemotherapeutics and anti-vascular drugs have synergistic effects is worth studying. This study is a phase II prospective clinical study of PD-1 inhibitor combined with bevacizumab and FOLFIRI regimen in the second-line treatment of unresectable recurrent or metastatic MSI-H colorectal cancer.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05035381
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Hongli Li, Dr.
Phone 86-22-23340123
Email [email protected]
Status Recruiting
Phase Phase 2
Start date January 1, 2019
Completion date December 30, 2022